// App-Quantinova.ai

5034 : Circulating tumor DNA (ctDNA) burden and actionable mutations in treatment-naive metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Alexander William Wyatt

Principal Investigators

  • Matti Annala

  • Sunil Parimi

  • Muhammad Zulfiqar

  • Daygen L. Finch

  • Conrad D. Oja

  • Joanna Vergidis

  • Arun Azad

  • Martin Gleave

  • Kim N. Chi

Medical Centers

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • Institute of Biosciences and Medical Technology, Tampere, Finland

  • British Columbia Cancer Agency, Abbotsford Centre, Vancouver, BC, Canada

  • British Columbia Cancer Agency, Abbotsford Centre, Vancouver, BC, Canada

  • British Columbia Cancer Agency, Southern Interior Centre, Kelowna, BC, Canada

  • British Columbia Cancer Agency, Abbotsford Centre, Vancouver, BC, Canada

  • BC Cancer Agency Vancouver Island Centre, Victoria, BC, Canada

  • Monash University, Victoria, Australia

Locations

  • Finland

  • Canada

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating DNA

  • Plasma cell-free DNA

Drug/Treatment

  • Enzalutamide

  • CB-7598

Outcome

  • Unknown

Study Design

  • Randomized

  • Cross Over

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved